BOCA RATON, Fla., Dec. 4 /PRNewswire/ -- Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, today announced the company's new management team as part of the formal completion of Biotest AG's acquisition of Nabi Pharmaceuticals (Nasdaq: NABI) and the creation of Biotest Pharmaceuticals. Please see the separate press release, "Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit," December 4, 2007 for more information.
"The team that we have assembled to run Biotest Pharmaceuticals
represents leaders from both Biotest AG and Nabi Pharmaceuticals. They are
proven professionals and bring to our new company extensive expertise in
research, development and business management," said Professor Dr. Gregor
Schulz, Chairman of the Management Board of Biotest AG. "We are confident
that, led by this team, Biotest Pharmaceuticals will become a U.S. leader
in the immunology biotherapeutic field."
Biotest Pharmaceuticals will be led by the following management team:
-- Chief Executive Officer - Rainer Pabst, PhD. Dr. Pabst is a biochemist
who previously served as Managing Director of Biotest Pharma GmbH.
Prior to that, he served as Vice President, Technical Operations for
Bayer Corp. Biological Products, Vice President Industrial Operations
at Centeon Pharma GmbH, and Head of Plasma Proteins Production at
Behringwerke AG. In his role as CEO, Dr. Pabst will be responsible for
the executive leadership and the operational execution of Biotest
-- Chief Financial Officer - Jordan I. Siegel, CPA, MBA. Mr. Siegel
previously served as Senior Vice President, Finance, Chief Financial
Officer and Treasurer for Nabi Biopharmaceuticals. Prior to joining
Nabi, he served as Vice President of Finance for IVAX Pharmaceuticals,
Inc and previously as IVAX's Vice
|SOURCE Biotest Pharmaceuticals Corp.|
Copyright©2007 PR Newswire.
All rights reserved